Comparative Cytogenetics of Drug Resistant and Sensitive Human Tumor Cells

Trent, Jeffrey M.

Abstract

The central theme of this project is to determine in a series of established human tumor cell lines how cytogenetic aberrations participate in the generation of acquired drug resistance. Three specific subprojects are proposed: 1) chromosome banding and in situ hybridization analysis of drug resistant compared to drug sensitive cell lines; 2) analysis of genomic instability associated with interruption of DNA synthesis; and 3) correlation of the temporal development of karyotypic (molecular biologic) alterations with specific biologic properties of drug resistant cells. We are hopeful that by combining chromosomal analysis with modern molecular and cellular biologic techniques, this research may provide a significant lead in understanding mechanisms of acquired drug resistance of direct relevance to clinical oncology.

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Cancer Institute (NCI)
• Type: Research Program Projects (P01)
• Project #: 5P01CA041183-08
• Application #: 3750613
• Support Year: 8
• Fiscal Year: 1994

Institution

• Name: University of Arizona
• City: Tucson
• State: AZ
• Country: United States
• Zip Code: 85721

Publications

Nelson, M A; Radmacher, M D; Simon, R et al. (2000) Chromosome abnormalities in malignant melanoma: clinical significance of nonrandom chromosome abnormalities in 206 cases. Cancer Genet Cytogenet 122:101-9

Simon, R; Desper, R; Papadimitriou, C H et al. (2000) Chromosome abnormalities in ovarian adenocarcinoma: III. Using breakpoint data to infer and test mathematical models for oncogenesis. Genes Chromosomes Cancer 28:106-20

Taetle, R; Aickin, M; Yang, J M et al. (1999) Chromosome abnormalities in ovarian adenocarcinoma: I. Nonrandom chromosome abnormalities from 244 cases. Genes Chromosomes Cancer 25:290-300

Taetle, R; Aickin, M; Panda, L et al. (1999) Chromosome abnormalities in ovarian adenocarcinoma: II. Prognostic impact of nonrandom chromosome abnormalities in 244 cases. Genes Chromosomes Cancer 25:46-52

Meloni-Ehrig, A M; Chen, Z; Guan, X Y et al. (1999) Identification of a ring chromosome in a myxoid malignant fibrous histiocytoma with chromosome microdissection and fluorescence in situ hybridization. Cancer Genet Cytogenet 109:81-5

Ozisik, Y Y; Meloni, A M; Spanier, S S et al. (1998) Deletion 1p in a low-grade chondrosarcoma in a patient with Ollier disease. Cancer Genet Cytogenet 105:128-33

Kline, R M; Oseas, R S; Jolley, S G et al. (1997) Leptomeningeal metastasis from a paraspinal rhabdomyosarcoma with a der(13)t(1;13)(q23;q32) in a 14-month-old boy. Cancer Genet Cytogenet 98:97-101

Kingsley, K L; Peier, A M; Meloni-Ehrig, A M et al. (1997) Cytogenetic findings in a bladder chondrosarcoma. Cancer Genet Cytogenet 96:183-4

Paine-Murrieta, G D; Taylor, C W; Curtis, R A et al. (1997) Human tumor models in the severe combined immune deficient (scid) mouse. Cancer Chemother Pharmacol 40:209-14

Thompson, F H; Taetle, R; Trent, J M et al. (1997) Band 1p36 abnormalities and t(1;17) in ovarian carcinoma. Cancer Genet Cytogenet 96:106-10